{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:02:41Z","timestamp":1774868561467,"version":"3.50.1"},"reference-count":54,"publisher":"Societatea Romana de Morfologie","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rom J Morphol Embryol"],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:p>Prostate cancer continues to be a health problem by epidemiological indicators, despite prevention and detection programs and advanced knowledge of molecular biology. Acinar forms are the most common and constitute a tumor group with a relatively good prognosis, but sometimes unpredictable compared to the associated histopathological (HP) parameters. Among the molecular mechanisms involved in tumor cell proliferation is the disruption of the cell cycle, and the evaluation of the expression of key proteins involved can assist the histological stratification of cases. The study investigated the immunoexpression of Cyclin D1, P53 and Ki67 in 55 prostatic acinar adenocarcinomas (PAAs), in relation to the HP prognostic parameters of the lesions. High reaction scores expressed as positivity index (PI) indicated the significant association of the three markers with increased grading groups recommended by International Society of Urological Pathology (ISUP), perineural and lymphovascular invasion. P53 PI and Ki67 PI were significantly or at the limit of significance increased in conventional and colloidal PAA, and in the case of P53 and in addition in advanced stages. Analysis of the effective values of the reactions indicated significant positive linear correlations between the investigated immunomarkers. The reactions were variable in a relatively homogeneous group of PAA and although they were generally associated with aggressive HP behavior, they seem useful in the punctual identification of cases that require a particular management, in the context of specific oncological therapy.<\/jats:p>","DOI":"10.47162\/rjme.66.4.06","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:10:17Z","timestamp":1774865417000},"page":"683-692","source":"Crossref","is-referenced-by-count":0,"title":["Immunoexpression of Cyclin D1, P53 and Ki67 in prostatic acinar adenocarcinomas"],"prefix":"10.47162","volume":"66","author":[{"name":"PhD Student, Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian Mihai","family":"Stoiculescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana Iulia","family":"Cre\u0163u","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca C\u0103t\u0103lina","family":"Andreiana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan \u015etefan","family":"Diaconescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Clinic of Urology I, Prof. Dr. Theodor Burghele Clinical Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petru Octavian","family":"Dr\u0103goescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Urology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex Emilian","family":"Stepan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"26736","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"\"[1] Giona S. The epidemiology of prostate cancer. In: Bott SRJ, Ng KL (eds). Prostate cancer [Internet]. Exon Publications, Brisbane, Australia, 2021 May 27, Chapter 1. https:\/\/doi.org\/10.36255\/exonpublications.prostatecancer.epidemiology.2021","DOI":"10.36255\/exonpublications.prostatecancer.epidemiology.2021"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"[2] Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin, 2025, 75(1):10-45. https:\/\/doi.org\/10.3322\/caac.21871","DOI":"10.3322\/caac.21871"},{"key":"ref2","unstructured":"[3] Kehinde EO, Al Maghrebi M, Anim JT. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol, 2008, 15(2):3967-3974."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"[4] Glaviano A, Singh SK, Lee EHC, Okina E, Lam HY, Carbone D, Reddy EP, O'Connor MJ, Koff A, Singh G, Stebbing J, Sethi G, Crasta KC, Diana P, Keyomarsi K, Yaffe MB, Wander SA, Bardia A, Kumar AP. Cell cycle dysregulation in cancer. Pharmacol Rev, 2025, 77(2):100030. https:\/\/doi.org\/10.1016\/j.pharmr.2024.100030","DOI":"10.1016\/j.pharmr.2024.100030"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"[5] Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Di\u00e9ras V, Slamon DJ. Palbociclib and Letrozole in advanced breast cancer. N Engl J Med, 2016, 375(20):1925-1936. https:\/\/doi.org\/10.1056\/NEJMoa1607303","DOI":"10.1056\/NEJMoa1607303"},{"key":"ref5","unstructured":"[6] Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res, 2000, 6(5):1891-1895."},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"[7] Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology, 2011, 58(5):781-789. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.03800.x","DOI":"10.1111\/j.1365-2559.2011.03800.x"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"[8] Carneiro A, Barbosa \u00c1RG, Takemura LS, Kayano PP, Moran NKS, Chen CK, Wroclawski ML, Lemos GC, da Cunha IW, Obara MT, Tobias-Machado M, Sowalsky AG, Bianco B. The role of immunohistochemical analysis as a tool for the diagnosis, prognostic evaluation and treatment of prostate cancer: a systematic review of the literature. Front Oncol, 2018, 8:377. https:\/\/doi.org\/10.3389\/fonc.2018.00377","DOI":"10.3389\/fonc.2018.00377"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"[9] Ofner H, Kramer G, Shariat SF, Hassler MR. TP53 deficiency in the natural history of prostate cancer. Cancers (Basel), 2025, 17(4):645. https:\/\/doi.org\/10.3390\/cancers17040645","DOI":"10.3390\/cancers17040645"},{"key":"ref9","unstructured":"[10] Sulik M, Guzi\u0144ska-Ustymowicz K, Darewicz B, Sulik A. Study of p53 protein expression in prostate cancer. Folia Histochem Cytobiol, 2001, 39(Suppl 2):197-198."},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"[11] Madani SH, Ameli S, Khazaei S, Kanani M, Izadi B. Frequency of Ki-67 (MIB-1) and P53 expressions among patients with prostate cancer. Indian J Pathol Microbiol, 2011, 54(4):688-691. https:\/\/doi.org\/10.4103\/0377-4929.91492","DOI":"10.4103\/0377-4929.91492"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"[12] Corti M, Lorenzetti S, Ubaldi A, Zilli R, Marcoccia D. Endocrine disruptors and prostate cancer. Int J Mol Sci, 2022, 23(3):1216. https:\/\/doi.org\/10.3390\/ijms23031216","DOI":"10.3390\/ijms23031216"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"[13] \u015eerban RE, Boldeanu MV, Florescu DN, Ionescu M, \u015eerb\u0103nescu MS, Boldeanu L, Florescu MM, Stepan MD, Obleag\u0103 VC, Constantin C, Popescu DM, Streba CT, Vere CC. Comparison between substance P and calcitonin gene-related peptide and their receptors in colorectal adenocarcinoma. J Clin Med, 2024, 13(18):5616. https:\/\/doi.org\/10.3390\/jcm13185616","DOI":"10.3390\/jcm13185616"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"[14] \u015eerban RE, Stepan MD, Florescu DN, Boldeanu MV, Florescu MM, \u015eerb\u0103nescu MS, Ionescu M, Streba L, Dr\u0103goescu NAM, Christopher P, Obleag\u0103 VC, Constantin C, Vere CC. Expression of calcitonin gene-related peptide and calcitonin receptor-like receptor in colorectal adenocarcinoma. Int J Mol Sci, 2024, 25(8):4461. https:\/\/doi.org\/10.3390\/ijms25084461","DOI":"10.3390\/ijms25084461"},{"key":"ref14","unstructured":"[15] Knudsen KE, Cavenee WK, Arden KC. D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res, 1999, 59(10):2297-2301."},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"[16] Tsai H, Morais CL, Alshalalfa M, Tan HL, Haddad Z, Hicks J, Gupta N, Epstein JI, Netto GJ, Isaacs WB, Luo J, Mehra R, Vessella RL, Karnes RJ, Schaeffer EM, Davicioni E, De Marzo AM, Lotan TL. Cyclin D1 loss distinguishes prostatic small-cell carcinoma from most prostatic adenocarcinomas. Clin Cancer Res, 2015, 21(24):5619-5629. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0744","DOI":"10.1158\/1078-0432.CCR-15-0744"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"[17] Nakamura Y, Felizola SJA, Kurotaki Y, Fujishima F, McNamara KM, Suzuki T, Arai Y, Sasano H. Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ER\u03b2) in human prostate cancer. Prostate, 2013, 73(6):590-595. https:\/\/doi.org\/10.1002\/pros.22599","DOI":"10.1002\/pros.22599"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"[18] Berlin A, Castro-Mesta JF, Rodriguez-Romo L, Hernandez-Barajas D, Gonz\u00e1lez-Guerrero JF, Rodr\u00edguez-Fern\u00e1ndez IA, Gonz\u00e1lez-Conchas G, Verdines-Perez A, Vera-Badillo FE. Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis. Urol Oncol, 2017, 35(8):499-506. https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.004","DOI":"10.1016\/j.urolonc.2017.05.004"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"[19] Song Z, Zhou Q, Zhang JL, Ouyang J, Zhang ZY. Marker Ki-67 is a potential biomarker for the diagnosis and prognosis of prostate cancer based on two cohorts. World J Clin Cases, 2024, 12(1):32-41. https:\/\/doi.org\/10.12998\/wjcc.v12.i1.32. Erratum in: World J Clin Cases, 2024, 12(36):6950-6951. https:\/\/doi.org\/10.12998\/wjcc.v12.i36.6950","DOI":"10.12998\/wjcc.v12.i36.6950"},{"key":"ref19","unstructured":"[20] World Health Organization (WHO) Classification of Tumours Editorial Board. Urinary and male genital tumors. WHO Classification of Tumours, 5th edition, International Agency for Research on Cancer (IARC) Press, Lyon, France, 2022."},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"[21] Testa U, Castelli G, Pelosi E. Cellular and molecular mechanisms underlying prostate cancer development: therapeutic implications. Medicines (Basel), 2019, 6(3):82. https:\/\/doi.org\/10.3390\/medicines6030082","DOI":"10.3390\/medicines6030082"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"[22] Podeanu MA, Vintilescu \u015eB, Sandu RE, Ionele CM, Niculescu CE, Florescu MM, \u015eelaru EL, Stepan MD. Ferritin as an inflammatory marker in pediatric metabolic syndrome: links to obesity and liver ultrasound alterations. Int J Mol Sci, 2025, 26(8):3793. https:\/\/doi.org\/10.3390\/ijms26083793","DOI":"10.3390\/ijms26083793"},{"key":"ref22","unstructured":"[23] Ciurea M, Ciurea R, Popa D, P\u00e2rv\u0103nescu H, Marinescu D, Vrabete M. Sinusoidal hemangioma of the arm: case report and review of literature. Rom J Morphol Embryol, 2011, 52(3):915-918."},{"key":"ref23","unstructured":"[24] Grecu AF, Popa DG, Lungulescu CV, Ciuc\u0103 EM, Camen A, Marinescu D, Nica O, Busuioc CJ, Ifrim Chen F, Ciurea ME. Histological findings from rat calvaria defect augmented with platelet-rich fibrin by using two consecutive periosteal incisions. Rom J Morphol Embryol, 2019, 60(1):111-118."},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"[25] Sherr CJ. D-type cyclins. Trends Biochem Sci, 1995, 20(5):187-190. https:\/\/doi.org\/10.1016\/s0968-0004(00)89005-2","DOI":"10.1016\/S0968-0004(00)89005-2"},{"key":"ref25","unstructured":"[26] Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE. Specificity of cyclin D1 for androgen receptor regulation. Cancer Res, 2003, 63(16):4903-4913."},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"[27] Comstock CES, Revelo MP, Buncher CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer, 2007, 96(6):970-979. https:\/\/doi.org\/10.1038\/sj.bjc.6603615","DOI":"10.1038\/sj.bjc.6603615"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"[28] Mohammed AA, Ibrahim HM, Atwa HA, Elshentenawy A, Elwan A. Impact of cyclin D1 and DJ-1 on diagnosis, clinico-pathological features and outcome in prostate cancer and benign prostatic hyperplasia. Forum Clin Oncol, 2019, 10(2):15-25. https:\/\/doi.org\/10.2478\/fco-2019-0005","DOI":"10.2478\/fco-2019-0005"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"[29] Zedan EM, Morgan NM, El-Sawi RM, Youssef SA. The study of Mucin stains and Cyclin D1 expression in benign prostatic hyperplasia and prostatic adenocarcinoma (Immunohistochemical study). Benha Med J. 2024, 41(6):73-86. https:\/\/doi.org\/10.21608\/bmfj.2024.267338.2011","DOI":"10.21608\/bmfj.2024.267338.2011"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"[30] Yu CC, Lin VC, Huang CY, Liu CC, Wang JS, Wu TT, Pu YS, Huang CH, Huang CN, Huang SP, Bao BY. Prognostic significance of cyclin D1 polymorphisms on prostate-specific antigen recurrence after radical prostatectomy. Ann Surg Oncol, 2013, 20(Suppl 3):S492-S499. https:\/\/doi.org\/10.1245\/s10434-013-2869-x","DOI":"10.1245\/s10434-013-2869-x"},{"key":"ref30","unstructured":"[31] Aaltomaa S, K\u00e4rj\u00e4 V, Lipponen P, Isotalo T, Kankkunen JP, Talja M, Mokka R. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res, 2006, 26(6C):4873-4878."},{"key":"ref31","unstructured":"[32] Ding GX, Liu J, Feng CC, Jiang HW, Xu JF, Ding Q. Slug regulates Cyclin D1 expression by ubiquitin-proteasome pathway in prostate cancer cells. Panminerva Med, 2012, 54(3):219-223."},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"[33] Zhou J, Lai Y, Peng S, Tang C, Chen Y, Li L, Huang H, Guo Z. Comprehensive analysis of TP53 and SPOP mutations and their impact on survival in metastatic prostate cancer. Front Oncol, 2022, 12:957404. https:\/\/doi.org\/10.3389\/fonc.2022.957404","DOI":"10.3389\/fonc.2022.957404"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"[34] Maddah MM, Hedayatizadeh-Omran A, Moosazadeh M, Alizadeh-Navaei R. Evaluation of the prognostic role of TP53 gene mutations in prostate cancer outcome: a systematic review and meta-analysis. Clin Genitourin Cancer, 2024, 22(6):102226. https:\/\/doi.org\/10.1016\/j.clgc.2024.102226","DOI":"10.1016\/j.clgc.2024.102226"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"[35] Zhang W, Dong Y, Sartor O, Zhang K. Deciphering the increased prevalence of TP53 mutations in metastatic prostate cancer. Cancer Inform, 2022, 21:11769351221087046. https:\/\/doi.org\/10.1177\/11769351221087046","DOI":"10.1177\/11769351221087046"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"[36] Verma R, Gupta V, Singh J, Verma M, Gupta G, Gupta S, Sen R, Ralli M. Significance of p53 and Ki-67 expression in prostate cancer. Urol Ann, 2015, 7(4):488-493. https:\/\/doi.org\/10.4103\/0974-7796.158507","DOI":"10.4103\/0974-7796.158507"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"[37] Kudahetti S, Fisher G, Ambroisine L, Foster C, Reuter V, Eastham J, M\u00f8ller H, Kattan MW, Cooper CS, Scardino P, Cuzick J, Berney DM. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer. BJU Int, 2009, 104(1):20-24. https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08407.x","DOI":"10.1111\/j.1464-410X.2009.08407.x"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"[38] Wahid Z, Jaffer R, Khalid S, Khan HA, Riaz S. Expression of p53 protein in prostate carcinoma and its correlation with Gleason grade. J Coll Physicians Surg Pak, 2020, 30(6):643-645. https:\/\/doi.org\/10.29271\/jcpsp.2020.06.643","DOI":"10.29271\/jcpsp.2020.06.643"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"[39] Ando K, Oki E, Saeki H, Yan Z, Tsuda Y, Hidaka G, Kasagi Y, Otsu H, Kawano H, Kitao H, Morita M, Maehara Y. Discrimination of p53 immunohistochemistry-positive tumors by its staining pattern in gastric cancer. Cancer Med, 2015, 4(1):75-83. https:\/\/doi.org\/10.1002\/cam4.346","DOI":"10.1002\/cam4.346"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"[40] Schlomm T, Iwers L, Kirstein P, Jessen B, K\u00f6llermann J, Minner S, Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A, Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A. Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol, 2008, 21(11):1371-1378. https:\/\/doi.org\/10.1038\/modpathol.2008.104","DOI":"10.1038\/modpathol.2008.104"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"[41] Stopsack KH, Salles DC, Vaselkiv JB, Grob ST, Mucci LA, Lotan TL. p53 immunohistochemistry to identify very high-risk primary prostate cancer: a prospective cohort study with three decades of follow-up. Eur Urol Oncol, 2023, 6(1):110-112. https:\/\/doi.org\/10.1016\/j.euo.2021.12.003","DOI":"10.1016\/j.euo.2021.12.003"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"[42] Kallakury BV, Figge J, Ross JS, Fisher HA, Figge HL, Jennings TA. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol, 1994, 25(1):92-97. https:\/\/doi.org\/10.1016\/0046-8177(94)90177-5","DOI":"10.1016\/0046-8177(94)90177-5"},{"key":"ref42","unstructured":"[43] Petrescu A, M\u00e2rzan L, Codreanu O, Niculescu L. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate carcinoma. Rom J Morphol Embryol, 2006, 47(2):143-146."},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"[44] Bhat G, Ahamed MA, Saroha N, Prasad G. Clinicopathological correlation of p53 expression in benign prostatic hyperplasia and prostate adenocarcinoma. Indian J Pathol Oncol, 2022, 9(1):60-64. https:\/\/doi.org\/10.18231\/j.ijpo.2022.015","DOI":"10.18231\/j.ijpo.2022.015"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"[45] Gesztes W, Schafer C, Young D, Fox J, Jiang J, Chen Y, Kuo HC, Mwamukonda KB, Dobi A, Burke AP, Moul JW, McLeod DG, Rosner IL, Petrovics G, Tan SH, Cullen J, Srivastava S, Sesterhenn IA. Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. Sci Rep, 2022, 12(1):5404. https:\/\/doi.org\/10.1038\/s41598-022-08826-5","DOI":"10.1038\/s41598-022-08826-5"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"[46] Niculescu \u015eA, Grecu DC, Simionescu CE, Niculescu EC, Stepan MD, Stepan AE. Immunoexpression of Ki67, p53 and cyclin D1 in osteosarcomas. Rom J Morphol Embryol, 2021, 62(3):743-750. https:\/\/doi.org\/10.47162\/RJME.62.3.11","DOI":"10.47162\/RJME.62.3.11"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"[47] Tretiakova MS, Wei W, Boyer HD, Newcomb LF, Hawley S, Auman H, Vakar-Lopez F, McKenney JK, Fazli L, Simko J, Troyer DA, Hurtado-Coll A, Thompson IM Jr, Carroll PR, Ellis WJ, Gleave ME, Nelson PS, Lin DW, True LD, Feng Z, Brooks JD. Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer Prostatic Dis, 2016, 19(3):264-270. https:\/\/doi.org\/10.1038\/pcan.2016.12","DOI":"10.1038\/pcan.2016.12"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"[48] di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer, 1992, 70(1 Suppl):254-268. https:\/\/doi.org\/10.1002\/1097-0142(19920701)70:1+<254::aid-cncr2820701312>3.0.co;2-e","DOI":"10.1002\/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"[49] Bakna M, Malik R, Jain P, Jain R, Jain A. Diagnostic and prognostic role of Ki-67 and cytokeratin-5 expression in BPH and carcinoma prostate. Int J Med Res Rev, 2016, 4(8):1484-1492. https:\/\/doi.org\/10.17511\/ijmrr.2016.i08.32","DOI":"10.17511\/ijmrr.2016.i08.32"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"[50] Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Reuter V, Eastham J, Moller H, Kattan MW, Gerald W, Cooper C, Scardino P, Cuzick J. Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer, 2009, 100(6):888-893. https:\/\/doi.org\/10.1038\/sj.bjc.6604951","DOI":"10.1038\/sj.bjc.6604951"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"[51] Zellweger T, G\u00fcnther S, Zlobec I, Savic S, Sauter G, Moch H, Mattarelli G, Eichenberger T, Curschellas E, R\u00fcfenacht H, Bachmann A, Gasser TC, Mihatsch MJ, Bubendorf L. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer, 2009, 124(9):2116-2123. https:\/\/doi.org\/10.1002\/ijc.24174","DOI":"10.1002\/ijc.24174"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"[52] Mohamed AA, Abbas MY, Alharbi H, Babiker AY. Assessment of expression of Ki-67 in benign and malignant prostatic lesions among Sudanese patients. Open Access Maced J Med Sci, 2018, 6(10):1809-1812. https:\/\/doi.org\/10.3889\/oamjms.2018.309","DOI":"10.3889\/oamjms.2018.309"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"[53] Albuquerque-Castro \u00c2, Macedo-Silva C, Oliveira-Sousa R, Const\u00e2ncio V, Lobo J, Carneiro I, Henrique R, Jer\u00f3nimo C. Redefining prostate cancer risk stratification: a pioneering strategy to estimate outcome based on Ki67 immunoscoring. Biomark Res, 2024, 12(1):75. https:\/\/doi.org\/10.1186\/s40364-024-00627-4. Erratum in: Biomark Res, 2024, 12(1):121. https:\/\/doi.org\/10.1186\/s40364-024-00670-1","DOI":"10.1186\/s40364-024-00670-1"},{"key":"ref53","unstructured":"[54] Ruhela S, Chadha S, Agarwal S. Analyzing the Gleason's score, Ki-67 index and p53 expression in prostate. Int J Acad Med Pharm, 2025, 7(3):110-113. https:\/\/doi.org\/10.47009\/jamp.2025.7.3.22\""}],"container-title":["Romanian Journal of Morphology and Embryology"],"original-title":[],"link":[{"URL":"https:\/\/rjme.ro\/RJME\/resources\/files\/660425683692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T10:12:18Z","timestamp":1774865538000},"score":1,"resource":{"primary":{"URL":"https:\/\/rjme.ro\/archive\/66\/4\/6\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":54,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,3,12]]},"published-print":{"date-parts":[[2026,3,12]]}},"URL":"https:\/\/doi.org\/10.47162\/rjme.66.4.06","relation":{},"ISSN":["1220-0522","2066-8279"],"issn-type":[{"value":"1220-0522","type":"print"},{"value":"2066-8279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]}}}